Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.
antiretroviral regimen (ART)
dolutegravir switch
previously documented virologic failure and prior exposure to mono/dual NRTI combination antiretroviral therapy
protease inhibitor/ritonavir (PI/r)
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
08
06
2020
accepted:
28
08
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Switching antiretroviral regimens when human immunodeficiency virus (HIV) viremia is controlled for a new regimen is challenging when there is the potential for prior nucleoside reverse-transcriptase inhibitor (NRTI) resistance. The objective was to study virologic outcomes after switching to dolutegravir compared with remaining on a boosted protease inhibitor (protease inhibitor/ritonavir [PI/r]) regimen in people with HIV (PWH) with prior documented virologic failure and/or exposure to mono/dual NRTIs. We used the Quebec HIV Cohort including 10 219 PWH whose data were collected at 4 sites in Montreal, Canada. We included all PWH with documented virologic failure or exposure to mono/dual NRTI therapy who were virologically suppressed on a PI/r-based regimen for at least 6 months on or after January 1, 2014 (n = 532). A marginal structural Cox model analysis was used to estimate the effect of the switch to dolutegravir on virologic outcome compared with remaining on PI/r. The outcome was defined as 2 consecutive viral loads (VLs) >50 copies/mL or 1 VL >50 copies/mL if it occurred at the last VL available. Among 532 eligible participants, 216 (40.6%) had their regimen switched to dolutegravir with 2 NRTIs, whereas 316 (59.4%) remained on the PI/r with 2 NRTIs. The weighted hazard ratio for the effect of dolutegravir switch on virologic failure compared with patients whose regimen remained on PI/r was 0.57 (95% confidence interval, 0.21-1.52). We did not find evidence of an increased risk for virologic failure after switching to dolutegravir from PI/r among patients with previous virologic failure or prior exposure to mono/dual NRTI.
Sections du résumé
BACKGROUND
BACKGROUND
Switching antiretroviral regimens when human immunodeficiency virus (HIV) viremia is controlled for a new regimen is challenging when there is the potential for prior nucleoside reverse-transcriptase inhibitor (NRTI) resistance. The objective was to study virologic outcomes after switching to dolutegravir compared with remaining on a boosted protease inhibitor (protease inhibitor/ritonavir [PI/r]) regimen in people with HIV (PWH) with prior documented virologic failure and/or exposure to mono/dual NRTIs.
METHODS
METHODS
We used the Quebec HIV Cohort including 10 219 PWH whose data were collected at 4 sites in Montreal, Canada. We included all PWH with documented virologic failure or exposure to mono/dual NRTI therapy who were virologically suppressed on a PI/r-based regimen for at least 6 months on or after January 1, 2014 (n = 532). A marginal structural Cox model analysis was used to estimate the effect of the switch to dolutegravir on virologic outcome compared with remaining on PI/r. The outcome was defined as 2 consecutive viral loads (VLs) >50 copies/mL or 1 VL >50 copies/mL if it occurred at the last VL available.
RESULTS
RESULTS
Among 532 eligible participants, 216 (40.6%) had their regimen switched to dolutegravir with 2 NRTIs, whereas 316 (59.4%) remained on the PI/r with 2 NRTIs. The weighted hazard ratio for the effect of dolutegravir switch on virologic failure compared with patients whose regimen remained on PI/r was 0.57 (95% confidence interval, 0.21-1.52).
CONCLUSIONS
CONCLUSIONS
We did not find evidence of an increased risk for virologic failure after switching to dolutegravir from PI/r among patients with previous virologic failure or prior exposure to mono/dual NRTI.
Identifiants
pubmed: 33204746
doi: 10.1093/ofid/ofaa404
pii: ofaa404
pmc: PMC7654378
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa404Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Lancet. 2010 Jan 30;375(9712):396-407
pubmed: 20074791
Lancet HIV. 2019 Sep;6(9):e576-e587
pubmed: 31307948
Clin Infect Dis. 2019 Sep 27;69(8):1320-1328
pubmed: 30590412
Int J Antimicrob Agents. 2019 Jul;54(1):35-42
pubmed: 30905695
Int J Biostat. 2010;6(2):Article 13
pubmed: 21969997
Pharmacotherapy. 2019 Apr;39(4):501-507
pubmed: 30723941
AIDS Res Ther. 2016 Sep 08;13(1):30
pubmed: 27617024
Lancet. 2017 Nov 4;390(10107):2063-2072
pubmed: 28867497
Clin Infect Dis. 2019 Feb 1;68(4):597-606
pubmed: 29912307
Lancet. 2014 Jun 28;383(9936):2222-31
pubmed: 24698485
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
Lancet Infect Dis. 2019 Mar;19(3):253-264
pubmed: 30732940
Lancet Infect Dis. 2014 Jul;14(7):581-9
pubmed: 24908551
Epidemiology. 2000 Sep;11(5):561-70
pubmed: 10955409
J Antimicrob Chemother. 2019 May 1;74(5):1376-1380
pubmed: 30668695
Lancet HIV. 2017 Dec;4(12):e536-e546
pubmed: 28729158
HIV Med. 2019 Feb;20(2):164-168
pubmed: 30457197
Int J Antimicrob Agents. 2018 May;51(5):733-738
pubmed: 29371105
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
Am J Epidemiol. 2016 Apr 15;183(8):758-64
pubmed: 26994063
Antivir Ther. 2017;22(4):295-305
pubmed: 28401876
Lancet Infect Dis. 2013 Nov;13(11):927-35
pubmed: 24074642
J Clin Virol. 2018 Aug;105:112-117
pubmed: 29957545
J Infect Dis. 2014 Aug 1;210(3):354-62
pubmed: 24446523
J Antimicrob Chemother. 2019 Mar 1;74(3):739-745
pubmed: 30476165
Clin Infect Dis. 2020 Jul 15;:
pubmed: 32668455
J Infect Dis. 2013 Mar 1;207(5):740-8
pubmed: 23225901
Lancet. 2017 Nov 4;390(10107):2073-2082
pubmed: 28867499
Lancet Infect Dis. 2014 Jul;14(7):590-9
pubmed: 24908550
Lancet. 2013 Mar 2;381(9868):735-43
pubmed: 23306000